FDA approved Zogenix’ single-entity hydrocodone product following a negative advisory committee meeting, and is facing ongoing opposition as the drug’s launch begins. The agency argues the risk is consistent with other extended-release opioids – and abuse-deterrent technology is too new to require.
Zogenix Inc.‘s launch of the long-acting hydrocodone formulation Zohydro will test the theory that there is no such thing as bad publicity.
The commercial availability of the new opioid pain therapy was hailed by headlines in national media outlets around the country...